|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Resolution of non-alcoholic steatohepatitis by rosuvastatin monotherapy in patients with metabolic syndrome显示文摘AIM: To investigate the effect of rosuvastatin monotherapy on non-alcoholic steatohepatitis(NASH). At present there is no effective treatment for non-alcoholic fatty liver disease or its advanced form NASH.METHODS: This prospective study included 20 biopsy proven patients with NASH, metabolic syndrome(Met S) and dyslipidaemia. Biochemical parameters of the blood of the patients and an ultrasonography of the liver were performed at baseline. Then patients receivedlifestyle advice and were treated for a 12 mo period with rosuvastatin(10 mg/d) monotherapy. Patients were re-evaluated during the study at 3 mo intervals, during which biochemical parameters of the blood were measured including liver enzymes. A repeat biopsy and ultrasonography of the liver were performed at the end of the study in all 20 patients. Changes in liver enzymes, fasting plasma glucose, serum creatinine, serum uric acid(SUA), high sensitivity C reactive protein(hs CRP) and lipid profile were assessed every 3 mo. The primary endpoint was the resolution of NASH and the secondary endpoints were the changes in liver enzyme and lipid values.RESULTS: The repeat liver biopsy and ultrasonography showed complete resolution of NASH in 19 patients, while the 20 th, which had no improvement but no deterioration either, developed arterial hypertension and substantial rise in triglyceride levels during the study, probably due to changes in lifestyle including alcohol abuse. Serum alanine transaminase, aspartate transaminase, and γ-glutamyl transpeptidase were normalised by the 3rd treatment month(ANOVA P < 0.001), while alkaline phosphatase activities by the 6th treatment month(ANOVA, P = 0.01). Fasting plasma glucose and glycated haemoglobin were significantly reduced(P < 0.001). Lipid values were normalised by the 3rd treatment month. No patient had Met S by the 9th treatment month. Body mass index and waist circumference remained unchanged during the study. Thus, changes in liver pathology and function should be attributed solely to rosuvastatin treatment. A limitation of the study is the absence of a control group.CONCLUSION: These findings suggest that rosuvastatin monotherapy could ameliorate biopsy proven NASH and resolve Met S within 12 mo. These effects and the reduction of fasting plasma glucose and SUA levels may reduce the risk of vascular and liver morbidity and mortality in NASH patients. These findings need confirmation in larger studies. | Konstantinos Kargiotis Vasilios G Athyros Olga Giouleme Niki Katsiki Evangelia Katsiki Panagiotis Anagnostis Chrysoula Boutari Michael Doumas Asterios Karagiannis Dimitri P Mikhailidis | 2015 | World Journal of Gastroenterology2015，21，25： | 18 |
| 2 | Management of erectile dysfunction in hypertension:Tips and tricks显示文摘Arterial hypertension is a major risk factor for cardiovascular disease and affects approximately one third of the adult population worldwide. The vascular origin of erectile dysfunction is now widely accepted in the vast majority of cases. Erectile dysfunction is frequently encountered in patients with arterial hypertension and greatly affects their quality of life of hypertensive patients and their sexual partners. Therefore, the management of erectile dysfunction in hypertensive patients is of paramount importance. Unfortunately, erectile dysfunction remains under-reported, under-recognized, and under-treated in hypertensive patients, mainly due to the lack of familiarity with this clinical entity by treating physicians. This review aims to discuss the more frequent problems in the management of hypertensive patients with erectile dysfunction and propose ways to overcome these problems in everyday clinical practice. | Margus Viigimaa Charalambos Vlachopoulos Antonios Lazaridis Michael Doumas | 2014 | World Journal of Cardiology2014，6，9： | 5 |
| 3 | Non-interventional management of resistant hypertension显示文摘Hypertension is one of the most popular fields of re-search in modern medicine due to its high prevalence and its major impact on cardiovascular risk and con-sequently on global health. Indeed, about one third of individuals worldwide has hypertension and is under increased long-term risk of myocardial infarction, stroke or cardiovascular death. On the other hand, resistant hypertension, the 'uncontrollable' part of arterial hy-pertension despite appropriate therapy, comprises a much greater menace since long-standing, high levels of blood pressure along with concomitant debilitating entities such as chronic kidney disease and diabetes mellitus create a prominent high cardiovascular risk milieu. However, despite the alarming consequences, resistant hypertension and its effective management still have not received proper scientific attention. As-pects like the exact prevalence and prognosis are yet tobe clarified. In an effort to manage patients with resis-tant hypertension appropriately, clinical doctors are still racking their brains in order to find the best therapeutic algorithm and surmount the substantial difficulties in controlling this clinical entity. This review aims to shed light on the effective management of resistant hyper-tension and provide practical recommendations for cli-nicians dealing with such patients. | Michael Doumas Costas Tsioufis Charles Faselis Antonios Lazaridis Haris Grassos Vasilios Papademetriou | 2014 | World Journal of Cardiology2014，6，10： | 5 |
| 4 | 顽固性高血压患者原发性醛固酮增多症的发病率:一项回顾性观察研究显示文摘背景:自1999年以来发表的多项研究表明,原发性醛固酬增多症(也称为“康恩综合征”)对超过10%的高血压患者有影响;然而,如此高的患病率也引起了争议。基于小样本研究,专家一般认为,顽固性高血压患者中原发性醛固酮增多症的患病率升高。本研究旨在评估大规模顽固性高血压患者原发性醛固酮增多症的患病率。方法:对前来门诊治疗的顽同性高血压患者(尽管应用3药联用方案,其中包括1种利尿剂, | Stella Douma Konstantinos Petidis Michael Doumas | 2008 | 世界临床医学2008，2，5： | 3 |
| 5 | Erectile dysfunction in chronic kidney disease:From pathophysiology to management显示文摘Chronic kidney disease(CKD) is encountered in millions of people worldwide,with continuously rising incidence during the past decades,affecting their quality of life despite the increase of life expectancy in these patients.Disturbance of sexual function is common among men with CKD,as both conditions share common pathophysiological causes,such as vascular or hormonal abnormalities and are both affected by similar coexisting comorbid conditions such as cardiovascular disease,hypertension and diabetes mellitus.The estimated prevalence of erectile dysfunction reaches 70% in end stage renal disease patients.Nevertheless,sexual dysfunction remains under-recognized and under-treated in a high proportion of these patients,a fact which should raise awareness among clinicians.A multifactorial approach in management and treatment is undoubtedly required in order to improve patients' quality of life and cardiovascular outcomes. | Eirini Papadopoulou Anna Varouktsi Antonios Lazaridis Chrysoula Boutari Michael Doumas | 2015 | World Journal of Nephrology2015，4，3： | 2 |
| 6 | Cardiovascular efficacy and safety of dipeptidyl peptidase-4 inhibitors:A meta-analysis of cardiovascular outcome trials显示文摘BACKGROUND Dipeptidyl peptidase-4(DPP-4)inhibitors are a generally safe and well tolerated antidiabetic drug class with proven efficacy in type 2 diabetes mellitus(T2DM).Recently,a series of large,randomized controlled trials(RCTs)addressing cardiovascular outcomes with DPP-4 inhibitors have been published.AIM To pool data from the aforementioned trials concerning the impact of DPP-4 inhibitors on surrogate cardiovascular efficacy outcomes and on major cardiac arrhythmias.METHODS We searched PubMed and grey literature sources for all published RCTs assessing cardiovascular outcomes with DPP-4 inhibitors compared to placebo until October 2020.We extracted data concerning the following“hard”efficacy outcomes:fatal and non-fatal myocardial infarction,fatal and non-fatal stroke,hospitalization for heart failure,hospitalization for unstable angina,hospitalization for coronary revascularization and cardiovascular death.We also extracted data regarding the risk for major cardiac arrhythmias,such as atrial fibrillation,atrial flutter,ventricular fibrillation and ventricular tachycardia.RESULTS We pooled data from 6 trials in a total of 52520 patients with T2DM assigned either to DPP-4 inhibitor or placebo.DPP-4 inhibitors compared to placebo led to a non-significant increase in the risk for fatal and non-fatal myocardial infarction[risk ratio(RR)=1.02,95%CI:0.94-1.11,I2=0%],hospitalization for heart failure(RR=1.09,95%CI:0.92-1.29,I2=65%)and cardiovascular death(RR=1.02,95%CI:0.93-1.11,I2=0%).DPP-4 inhibitors resulted in a non-significant decrease in the risk for fatal and non-fatal stroke(RR=0.96,95%CI:0.85-1.08,I2=0%)and coronary revascularization(RR=0.99,95%CI:0.90-1.09,I2=0%),Finally,DPP-4 inhibitors demonstrated a neutral effect on the risk for hospitalization due to unstable angina(RR=1.00,95%CI:0.85-1.18,I2=0%).As far as cardiac arrhythmias are concerned,DPP-4 inhibitors did not significantly affect the risk for atrial fibrillation(RR=0.95,95%CI:0.78-1.17,I2=0%),while they were associated with a significant increase in the risk for atrial flutter,equal to 52%(RR=1.52,95%CI:1.03-2.24,I2=0%).DPP-4 inhibitors did not have a significant impact on the risk for any of the rest assessed cardiac arrhythmias.CONCLUSION DPP-4 inhibitors do not seem to confer any significant cardiovascular benefit for patients with T2DM,while they do not seem to be associated with a significant risk for any major cardiac arrhythmias,except for atrial flutter.Therefore,this drug class should not be the treatment of choice for patients with established cardiovascular disease or multiple risk factors,except for those cases when newer antidiabetics(glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors)are not tolerated,contraindicated or not affordable for the patient. | Dimitrios Ioannis Patoulias Aristi Boulmpou Eleftherios Teperikidis Alexandra Katsimardou Fotios Siskos Michael Doumas Christodoulos E Papadopoulos Vassilios Vassilikos | 2021 | World Journal of Cardiology2021，13，10： | 2 |
| 7 | Cardiovascular risk across the histological spectrum and the clinical manifestations of non-alcoholic fatty liver disease:an update显示文摘 | Vasilios G Athyros Konstantinos Tziomalos Niki Katsiki Michael Doumas Asterios Karagiannis Dimitri P Mikhailidis | 2015 | World Journal of Gastroenterology2015，，22： | 2 |
| 8 | Antihypertensive Treatment and Sexual Dysfunction显示文摘 | Athanasios Manolis Michael Doumas | 2012 | Current Hypertension Reports2012，，4： | 1 |
| 9 | Exercise Capacity and Progression From Prehypertension to Hypertension显示文摘 | Charles Faselis Michael Doumas John Peter Kokkinos Demosthenes Panagiotakos Raya Kheirbek Helen M. Sheriff Katherine Hare Vasilios Papademetriou Ross Fletcher Peter Kokkinos | 2012 | Hypertension2012，，2： | 1 |
| 10 | Carotid Baroreceptor Activation for the Treatment of Resistant Hypertension and Heart Failure显示文摘 | Michael Doumas Charles Faselis Costas Tsioufis Vasilios Papademetriou | 2012 | Current Hypertension Reports2012，，3： | 1 |
| 11 | Should ambulatory blood pressure monitoring be mandatory for future studies in resistant hypertension: a perspective显示文摘 | Michael Doumas Panagiota Anyfanti George Bakris | 2012 | Journal of Hypertension2012，，5： | 1 |
| 12 | Hypertension and sexual dysfunction: time to act显示文摘 | Margus Viigimaa Michael Doumas Charalampos Vlachopoulos Panagiota Anyfanti Jacek Wolf Krzysztof Narkiewicz Giuseppe Mancia | 2011 | Journal of Hypertension2011，，2： | 1 |
| 13 | Renal sympathetic denervation in hypertension显示文摘 | Michael Doumas Charles Faselis Vasilios Papademetriou | 2011 | Current Opinion in Nephrology and Hypertension2011，，6： | 1 |
| 14 | Exercise Capacity and Mortality in Older Men: A 20-Year Follow-Up Study显示文摘 | Peter Kokkinos Jonathan Myers Charles Faselis Demosthenes B. Panagiotakos Michael Doumas Andreas Pittaras Athanasios Manolis John Peter Kokkinos Pamela Karasik Michael Greenberg Vasilios Papademetriou Ross Fletcher | 2010 | Circulation2010，，8： | 1 |
| 15 | Renal Sympathetic Denervation and Systemic Hypertension显示文摘 | Michael Doumas Charles Faselis Vasilios Papademetriou | 2010 | The American Journal of Cardiology2010，，4： | 1 |
| 16 | Renal sympathetic denervation: the jury is still out显示文摘 | Michael Doumas Stella Douma | 2010 | The Lancet2010，，9756： | 1 |
| 17 | A graded association of exercise capacity and all-cause mortality in males with high-normal blood pressure显示文摘 | Peter Kokkinos Michael Doumas Jonathan Myers Charles Faselis Athanasios Manolis Andreas Pittaras John Peter Kokkinos Vasilios Papademetriou Steven Singh Ross D. Fletcher | 2009 | Blood Pressure2009，，5： | 1 |
| 18 | Interventional management of resistant hypertension显示文摘 | Michael Doumas Stella Douma | 2009 | The Lancet2009，，9671： | 1 |
| 19 | Exercise Capacity and Mortality in Hypertensive Men With and Without Additional Risk Factors显示文摘 | Peter Kokkinos Athanasios Manolis Andreas Pittaras Michael Doumas Angeliki Giannelou Demosthenes B. Panagiotakos Charles Faselis Puneet Narayan Steven Singh Jonathan Myers | 2009 | Hypertension2009，，3： | 1 |
| 20 | Prevalence of primary hyperaldosteronism in resistant hypertension: a retrospective observational study显示文摘 | Stella Douma Konstantinos Petidis Michael Doumas Panagiota Papaefthimiou Areti Triantafyllou Niki Kartali Nikolaos Papadopoulos Konstantinos Vogiatzis Chrysanthos Zamboulis | 2008 | The Lancet2008，，9628： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员